The Ras/MAPK (RAF/MEK/ERK) pathway plays a central role in regulating mammalian cell growth, differentiation, and survival by relaying extracellular signals from ligand bound cell surface tyrosine kinase receptors, making it an excellent target for treatment for cancers with activation of this pathway. This poster presents the identification of the initial hit from ALIS (Automated Ligand Identification System) and the optimization of the hit towards MK 8353. The modifications were required to improve activity, pharmacokinetics, and off target activity (HERG and CYP), while maintaining the novel movements of the glycine rich loop which opens up a new cavity for interaction with the inhibitor and ERK, allowing for better selectivity against other Kinases. MK 8353 was found to have an overall response rate of 20% (evaluable patients) during its Phase 1a/2b MK 8353 001 clinical trial.
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